Chronic hepatitis C (CHC) infection and alcoholic liver disease are among the most common causes for advanced liver disease worldwide and frequently coexist. Heavy alcohol use has clearly been demonstrated to accelerate liver fibrosis progression [1] [2] [3] [4] [5] [6] , increasing cirrhosis and decompensated liver disease risk [7] .
Although heavy alcohol use is clearly detrimental to the health of patients with CHC, it is unclear whether consumption of smaller quantities of alcohol impacts fibrosis progression. Many patients with CHC consume alcohol and are unable or unwilling to completely abstain. Some studies have suggested a linear dose-response on fibrosis progression even at lower quantities, whereas others have not clearly demonstrated a risk for fibrosis progression <20-50 g of alcohol per day [5, [8] [9] [10] [11] [12] [13] . Patients coinfected with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) have accelerated fibrosis progression compared with HCV-monoinfected individuals. Whether regular consumption of small quantities of alcohol further increases the rate of fibrosis progression is unknown. For this reason, we sought to examine the impact of moderate alcohol use on liver fibrosis progression in a well-characterized cohort of women coinfected with HIV and HCV.
PATIENTS AND METHODS

Population
The Women's Interagency HIV Study (WIHS) is a prospective, multicenter, longitudinal observational cohort of adult women infected with HIV or at high risk of acquiring HIV. Details of the WIHS cohort have been described elsewhere [14, 15] . Among the 3766 women enrolled in the first 2 recruitment waves (cohort 1 = 1994-1995; cohort 2 = 2001-2002), 18% were HIV/HCV coinfected at WIHS entry and included in this analysis (n = 686).
The study was approved by each site's institutional review board and all women gave informed consent at entry. HCV infection was defined by positive serum HCV RNA at WIHS entry.
Data Collection
Patients were seen in follow-up every 6 months, where detailed sociodemographic (age, ethnicity, race, and past substance use), medical and behavioral data were collected through structured interviews, physical examination, and biologic specimen collection. Biologic specimens were collected every 6 months including liver enzymes, renal function, complete blood count, CD4 cell count, and HIV viral load. HIV RNA was measured using isothermal nucleic acid sequence-based amplification (NASBA/ Nuclisens) method (bioMérieux, Durham, North Carolina) with a lower limit of detection of 80 copies/mL. Highly active antiretroviral therapy was defined by the contemporaneous Department of Health and Human Services guidelines [16] . Second-or third-generation enzyme-linked immunoassays were utilized for HCV antibody detection (Ortho-Diagnostic Systems, Rochester, New York) and confirmed by documenting HCV RNA seropositivity (Quantiplex 2.0 branched chain DNAenhanced label amplification assay; Bayer-Versant Diagnostics, Emeryville, California) and by reverse-transcription polymerase chain reaction (COBAS Amplicor HCV Detection Kit, Roche Diagnostic Systems, Pleasanton, California). The presence of hepatitis B surface antigenemia was assessed within the first year of enrollment. Data including body mass index (BMI), history of hypertension, diabetes, and insulin resistance were collected at each study visit. Diabetes was defined as any fasting glucose measurement of >126 mg/dL, hemoglobin A1c measured at ≥6.5%, or self-report of taking antidiabetic medication.
Drug and Alcohol Use
Injection drug use (IDU) and non-IDU was assessed at the entry and subsequent follow-up visits. Alcohol intake was ascertained semiannually by average number of drinks per week during the preceding 6-month interval. Light use was defined as 1-3 drinks per week, moderate as 4-7 drinks per week, and heavy use as >7 drinks per week. Heavy users were substratified into 2 groups: 8-14 drinks per week, and >14 drinks per week, to reflect variable country-specific cutoffs for heavy use [17] . Participants were considered to be abstinent if no alcohol use was reported at WIHS entry and throughout all follow-up visits, and formed the reference group. Years of alcohol exposure within each category of use was cumulated from study entry throughout the course of the observation period, and the concurrent values of the resulting cumulative exposure variables were used as predictors of each Fibrosis-4 Index for Liver Fibrosis (FIB-4) measurement.
Fibrosis Measurements
Noninvasive fibrosis measurements including FIB-4 and AST to platelet ratio index (APRI) have been validated in patients with HIV/HCV coinfection as well as this cohort [18] [19] [20] [21] [22] . FIB-4, defined as (age × aspartate aminotransferase [AST]) / (platelets × alanine aminotransferase [ALT]), was calculated annually in WIHS participants. Standard cutoffs of FIB-4 were used to define no fibrosis (<1.5) and significant fibrosis (>3.25) for each measure. FIB-4 values were considered invalid if AST or ALT was >10 times the upper limit of normal or platelet counts were <25 000 10 6 cells/L, as these extremes values are unlikely to be due to chronic liver fibrosis, and more likely to be caused by acute hepatitis or another disease process.
Primary Outcome
The primary outcome of this study was rate of fibrosis progression, defined as change in FIB-4 per year.
Statistical Analysis
Sociodemographic and clinical characteristics of WIHS women at study entry were described using mean (standard deviation We used statistical models that reflect the gradual, cumulative nature of fibrosis progression. We modeled all FIB-4 measurements together in a random-intercept, random-slope regression model. The random intercepts accounted for between-woman differences in FIB-4 at study entry, which allowed the model to focus on within-woman fibrosis progression during the study. We modeled the effect of alcohol consumption in terms of the woman's cumulative years as study entry that she spent in each nonabstinent alcohol consumption category up to each FIB-4 measurement, so that regression coefficients estimated the effect of alcohol consumption on the rate of fibrosis progression. Other covariates were modeled similarly, except for age and HIV viral load. Age is already a cumulative measure over time, so we used current age at the time of each FIB-4 measurement to model average rates of progression in the absence of any other factors that increase or decrease them. We used linear splines to allow these average rates to differ in different age ranges: <40, 40-45 inclusive, >45-50, >50-55, and >55. We modeled the effect of HIV viral load continuously using detectable log 10 viral load years, defined as the area under the time-log 10 viral load curve and >80 copies/mL; the coefficient for this variable therefore estimates the acceleration in fibrosis progression for each factor of 10 increase in HIV viral load. For all covariates, we carried the most recent measurement forward in time until a new measurement became available, but considered it to be missing after more than a year had passed since the last available measurement. Patient follow-up was censored such that imputation of missing data never exceeded 1 year. To best focus on HIV/HCV-coinfected women, we excluded all observations that occurred after a woman started HCV treatment or had an undetectable HCV viral load. Forward stepwise selection (P < .05 for model inclusion) was used to build the multivariable model with alcohol use included as the primary independent factor of interest. Resulting β-coefficients and 95% confidence intervals (95% CIs) estimated the increase or decrease in the rate of FIB-4 progression per year. We also evaluated fibrosis progression using APRI; as results were similar regarding our primary independent variable, alcohol consumption, only results for FIB-4 are presented. Table 1 summarizes the cohort entry characteristics of the 686 women included in this analysis. Two women did not have entry alcohol use recorded and were excluded from Table 1 but included in fibrosis progression analysis. The mean age of the study population was 40 (SD, 6) years at entry. The majority (62.7%) of women were African American and had HCV genotype 1 (87.5%) with mean HCV viral load 14.2 log 10 (SD, 2) IU/mL. Median HIV viral load was 18.0 (IQR, 2.7-88) IU/mL and median CD4 count at entry was 351 (IQR, 198-548) cells/μL. Nearly one-third (28.6%) of women were receiving antiretroviral therapy (ART) at WIHS entry. Median FIB-4 score at entry was 1.42 (IQR, 1.00-2.10), and 11% (n = 72) of women had evidence of significant fibrosis (FIB-4 >3.25). Median follow-up was 10.0 (IQR, 4.2-17.7) years. Within the entire cohort, a total of 15% (n = 103) received interferon-based HCV treatment and 13 achieved sustained virologic response.
RESULTS
Study Population
At WIHS entry, 46% of women reported no alcohol use, and 27% reported light, 7% moderate, and 20% heavy alcohol use (>7 drinks per week) in the 6 months prior to WIHS entry. Among the 135 women who reported heavy alcohol use at WIHS entry, about one-third (n = 46) drank ≤14 drinks per week, whereas two-thirds (n = 89) reported >14 drinks per week. When compared to women abstinent at WIHS entry, those who consumed alcohol at cohort entry were more likely to smoke tobacco and report illicit drug use, both IDU and non-IDU. Women with higher entry categories of alcohol use were less likely to be on ART at study entry and had lower BMI.
Alcohol Use in Women's Interagency HIV Study Follow-up
Alcohol use varied through WIHS follow-up, with 30.5% increasing mean alcohol consumption, 14.5% decreasing, and 
Predictors of Fibrosis Progression
Thirty percent (n = 182) of women without significant fibrosis at cohort entry developed cirrhosis (FIB-4 >3. This includes averaged data from Women's Interagency HIV Study entry and follow-up so that only women who were abstinent from entry and every follow-up visit have average alcohol use of 0 (n = 159). Women with average use >0 but <1 were included in the 1-3 drinks/week category Gray text denotes average alcohol use in follow-up greater than at entry, italic text denotes average alcohol use in follow-up less than at entry, and bolded black text denotes no change in average follow-up use as compared to entry use.
year [95% CI, -.027 to .344]; P = .09) after controlling for age, race/ethnicity, and viral load. Table 4) . Results were similar when fibrosis progression was evaluated with APRI instead of FIB-4 (data not shown).
DISCUSSION
Heavy alcohol use has clearly been shown to negatively impact health, accounting for 5.9% of all global deaths, and worsening >200 diseases including liver disease [23] . As such, many countries have guidelines for maximum daily/weekly alcohol consumption [17] . Even within the general population, there is no consensus regarding "safe" limits for alcohol. Further ambiguity exists regarding the safety of modest alcohol use in patients with established liver disease from disorders other than alcohol, including chronic HCV infection. National Health and Nutrition Examination Survey data [24] suggest that individuals with CHC have higher rates of alcohol use, with these individuals almost 3 times more likely to have >1 drink per day and 8 times more likely to have ≥3 drinks per day or binge drink (>5 drinks per day). Furthermore, some studies suggest that women are at higher risk for fibrosis progression and death with excessive alcohol use, possibly due to increased bioavailability [25] [26] [27] . Although many propose complete abstinence as the only safe option in those with chronic viral hepatitis, this may not be feasible for all patients with CHC, especially those with other comorbid illnesses including mental health and substance use disorders. In this study, we found that light or moderate alcohol use (≤7 drinks per week) was associated with little change in fibrosis progression rate as measured by FIB-4 in long-term follow-up of HIV/HCV-coinfected women. Women with light or moderate alcohol use in follow-up had similar fibrosis progression rates as women abstinent from alcohol throughout the duration of follow-up. Conversely, women with heavy alcohol use (>7 drinks per week) showed trends toward greater fibrosis progression, compared with abstinent women, primarily driven by periods with >14 drinks per week. In addition to alcohol, fibrosis progression was also associated with Hispanic and white race/ethnicity (as compared to African American), older age, and higher HIV viral load [28] [29] [30] . We have previously shown that African American race is associated with decreased fibrosis progression and liver-related deaths in WIHS HIV/HCVcoinfected women [31] . Of interest, despite WIHS research clinicians recommending limiting or avoiding alcohol at semiannual visits, most women who consumed alcohol at WIHS entry continued to have periods of alcohol use in follow-up.
This suggests that despite being enrolled in a long-term observational cohort study, patients did not change their drinking behaviors, limiting any potential bias in changing behaviors due to participation in a research study.
The impact of nonheavy alcohol use on fibrosis progression in CHC is not well described, especially in women. Definitions for nonheavy use fluctuate widely from study to study [8, 32, 33] , and most studies do not employ sex-specific cutoffs. Many women were misclassified as moderate alcohol users when they should have been classified as being heavy alcohol users on the basis of guidelines for nonhazardous drinking in women without underlying liver disease. Not surprisingly, study conclusions vary, with some showing no impact of light alcohol use on fibrosis progression [8] and other suggesting accelerated fibrosis with alcohol use. This is the first study specifically evaluating the impact of moderate alcohol use in HIV/HCV-coinfected women. Additionally, this is one of the few studies evaluating the longterm impact of ongoing nonheavy alcohol exposure on the natural history of CHC. Previous studies of alcohol in patients with HCV included few women, and even fewer women contributing data to heavy alcohol use groups. In this study, >40% of women had periods of heavy use, and almost 80% of women had at least some alcohol consumption during WIHS follow-up. We used conservative, sex-specific alcohol use categories, more reflective of current National Institute on Alcohol Abuse and Alcoholism guidelines [17] , for the general population and better representative of "moderate" use. Follow-up time was long in this cohort, which helped us evaluate the long-term consequences of light alcohol use on fibrosis progression.
There are several limitations to this study. Current alcohol use was captured at study entry and in follow-up, but lifetime alcohol exposure was not collected. Abstinence was defined as no alcohol use in the 6 months prior to WIHS entry as well as throughout follow-up. Women categorized as abstinent may have had a prior history of alcohol use. Some of these women may represent "sick abstainers" that have ceased alcohol consumption due to the severity of their liver disease. This may explain the finding that entry fibrosis scores were similar between groups, when one would expect heavy users to have higher fibrosis scores as compared to abstinent patients. Nonetheless, the focus of this study was on fibrosis progression during study follow-up, when remote alcohol use would not be expected to impact current fibrosis progression rates. Moreover, our reallife cohort represents clinical practice where many patients have a history of prior alcohol use, which often cannot be accurately quantified. Alcohol intake was ascertained through self-report; women may have underreported actual usage. Short-term heavy alcohol use can transiently raise AST and FIB-4, and underreporting may lead to higher-than-expected fibrosis progression rates as measured by FIB-4. Although many women contributed data to the heavy use group (>7 drinks per week), considerably fewer women had periods of heavy use as compared to light use and the time spent in the heavy use category was relatively short (median, 1 year). As such, our estimates are less precise in this group. Nonetheless, heavy alcohol use has clearly been established as predictive of fibrosis progression in other studies, and was not the focus of this analysis. Many women contributed significant data to light and moderate use categories (3358, 1220, 353, and 690 person-years of observation time, respectively). Our results are sufficiently precise, with confidence intervals centered around the null, to provide evidence that that modest alcohol use did not significantly increase rates of fibrosis progression with adequate observation time to reasonably adjust for confounding in our statistical analyses. Finally, FIB-4 is a noninvasive modality for estimating liver fibrosis, but is less accurate than liver biopsy or transient elastography [34] [35] [36] [37] . However, it has been validated in patients with HIV/HCV coinfection, as well as specifically in this cohort [19, 20] CONCLUSIONS Alcohol use is common in HIV/HCV-coinfected women. Nonetheless, light and moderate alcohol use (≤7 drinks per week) was not shown to substantially increase liver fibrosis progression in this long-term cohort study, whereas heavy alcohol use was associated with accelerated liver damage. Women with HIV/HCV coinfection should be counseled to minimize alcohol consumption, but complete abstinence may not be required to prevent accelerated fibrosis progression. 
